NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate

Authors propose imposing penalties on drugmakers who don't start confirmatory trials shortly after accelerated approval and additional discounts for public payers; proposals could pick up steam among congressional democrats amid their renewed call for lower drug prices.